Iridex’s MicroPulse technology shows efficacy in glaucoma management study

Iridex (IRIX) announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse technology can safely and effectively further reduce intraocular pressure, or IOP, in patients with glaucoma. The study aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment. Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases.